# Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

> **NCT03532217** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer

## Interventions

- **BIOLOGICAL:** PROSTVAC-V
- **BIOLOGICAL:** PROSTVAC-F
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **BIOLOGICAL:** Neoantigen DNA vaccine
- **DEVICE:** TriGrid Delivery System
- **PROCEDURE:** Tumor biopsy
- **PROCEDURE:** Peripheral blood
- **PROCEDURE:** Fecal samples
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT03532217
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-07-25
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532217, "Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03532217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*